## Cost-Effectiveness of Screening and Optimal Manageme Chronic Kidney Disease: A Modeled Analysis

Value in Health 13, 196-208

DOI: 10.1111/j.1524-4733.2009.00668.x

Citation Report

#	Article	IF	CITATIONS
1	Cost–Benefit Estimation of Cadaveric Kidney Transplantation: The Case of a Developing Country. Transplantation Proceedings, 2011, 43, 2300-2304.	0.3	21
2	Is chronic hepatitis B being undertreated in the United States?. Journal of Viral Hepatitis, 2011, 18, 377-383.	1.0	153
3	Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews, 2011, 33, 63-87.	1.3	70
4	Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrology Dialysis Transplantation, 2012, 27, 1396-1402.	0.4	42
5	A Decade After the KDOQI CKD Guidelines: A Perspective From Australia. American Journal of Kidney Diseases, 2012, 60, 725-726.	2.1	3
6	Screening for Chronic Kidney Disease. , 2012, , .		1
7	The Health Profile and Chronic Diseases Comorbidities of US-Bound Iraqi Refugees Screened by the International Organization for Migration in Jordan: 2007–2009. Journal of Immigrant and Minority Health, 2013, 15, 1-9.	0.8	62
8	Opportunistic inâ€hospital screening for kidney disease using the <scp>K</scp> idney <scp>H</scp> ealth <scp>C</scp> heck. Nephrology, 2014, 19, 693-698.	0.7	5
9	Cost-Effectiveness of Kidney Transplantation From DCD in Italy. Transplantation Proceedings, 2014, 46, 3289-3296.	0.3	32
10	Cost-effectiveness of Primary Screening for CKD: A Systematic Review. American Journal of Kidney Diseases, 2014, 63, 789-797.	2.1	177
11	Screening, Early Diagnosis, Genetic Markers, and Predictors of Diabetic Nephropathy., 2014, , 79-89.		0
12	Management of kidney disease in patients with diabetes in the primary care setting. Primary Care Diabetes, 2014, 8, 159-163.	0.9	5
13	Original article. Cost-effectiveness of annual microalbuminuria screening in Thai diabetics. Asian Biomedicine, 2014, 8, 371-379.	0.2	9
14	Cost to government and society of chronic kidney disease stage 1–5: a national cohort study. Internal Medicine Journal, 2015, 45, 741-747.	0.5	53
15	Methods Used in Economic Evaluations of Chronic Kidney Disease Testing — A Systematic Review. PLoS ONE, 2015, 10, e0140063.	1.1	13
16	Risk Prediction for Early CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1371-1379.	2.2	97
17	Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care. Journal of Managed Care & Diabetes Care. 2016, 22, 40-48.	0.5	4
18	Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam. PLoS ONE, 2016, 11, e0155699.	1.1	28

#	Article	IF	CITATIONS
19	A systematic review of economic evaluations of screening programmes for cardiometabolic diseases. European Journal of Public Health, 2016, 27, ckw237.	0.1	8
20	Costâ€effectiveness of a riskâ€based secondary screening programme of type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 710-729.	1.7	8
21	Long-Term and Interactive Effects of Pay-For-Performance Interventions among Diabetic Nephropathy Patients at the Early Chronic Kidney Disease Stage. Medicine (United States), 2016, 95, e3282.	0.4	11
22	The Potential Impact of Public Health Interventions in Preventing Kidney Disease. Seminars in Nephrology, 2017, 37, 234-244.	0.6	8
23	Providing Coverage for the Unique Lifelong Health Care Needs of Living Kidney Donors Within the Framework of Financial Neutrality. American Journal of Transplantation, 2017, 17, 1176-1181.	2.6	16
24	A Systematic Review of Economic Evidence on Community Hypertension Interventions. American Journal of Preventive Medicine, 2017, 53, S121-S130.	1.6	32
25	Use of Intraoperative Duplex Ultrasound and Resistance Index Reduces Complications in Living Renal Donor Transplantation. Transplantation Proceedings, 2018, 50, 3192-3198.	0.3	6
26	The Caring Costs for Patients Bearing Chronic Kidney Disease (CKD), in a Non-dialytic Phase of a University Hospital / O Custo do Atendimento aos Pacientes com Doença Renal Crônica (Drc), em Fase Não DialÃtica de um Hospital Universitário. Revista De Pesquisa: Cuidado é Fundamental Online, 2018, 10. 647-655.	0.5	3
27	Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. Pharmacoeconomics, 2019, 37, 1451-1468.	1.7	24
28	Patient and provider factors associated with enrolment in the pre-end-stage renal disease pay-for-performance programme in Taiwan: a cross-sectional study. BMJ Open, 2019, 9, e031354.	0.8	2
29	The screening for chronic kidney disease among older people across Europe (SCOPE) project: findings from cross-sectional analysis. BMC Geriatrics, 2020, 20, 316.	1.1	6
30	The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening. BMC Nephrology, 2020, 21, 73.	0.8	2
31	Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?. Diabetes Care, 2020, 43, 1557-1592.	4.3	98
32	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
33	Prevalence and awareness of chronic kidney disease among adult diabetic outpatients in Northeast Ethiopia. BMC Nephrology, 2020, 21, 129.	0.8	11
34	Health screening for emerging non-communicable disease burdens among the global poor: Evidence from sub-Saharan Africa. Journal of Health Economics, 2021, 75, 102388.	1.3	10
35	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. CKJ: Clinical Kidney Journal, 2021, 14, 1719-1730.	1.4	41
36	Assessment of chronic disease management mode (CDMM) on participants with primary hypertension. Tropical Medicine and International Health, 2021, 26, 829-837.	1.0	5

3

#	ARTICLE	IF	CITATIONS
37	An Analyticsâ€Driven Approach for Optimal Individualized Diabetes Screening. Production and Operations Management, 2021, 30, 3161-3191.	2.1	8
38	The current state and future of internet technology-based hypertension management in Japan. Hypertension Research, 2021, 44, 276-285.	1.5	14
39	Costâ€utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology, 2019, 24, 56-64.	0.7	34
40	Effectiveness, cost effectiveness, acceptability and implementation barriers/facilitators of chronic kidney disease management programs and models of care for Aboriginal and Torres Strait Islander Australians: a mixed methods systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports. 2015. 13. 65-86.	1.7	1
41	An economic evaluation of pre-dialysis stage of chronic kidney disease. Farmakoekonomika, 2021, 14, 365-378.	0.4	1
42	Effectiveness, cost effectiveness, acceptability and implementation barriers/facilitators of chronic kidney disease management programs and models of care for Aboriginal and Torres Strait Islander Australians: a mixed methods systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports. 2015. 13. 65-86.	1.7	O
43	Kidney Disease., 2017,, 235-252.		1
45	China county-based prostate specific antigen screening for prostate cancer and a cost-effective analysis. Translational Andrology and Urology, 2021, 10, 3787-3799.	0.6	6
48	Global proteinuria guidelines: are we nearly there yet?. Clinical Biochemist Reviews, 2011, 32, 89-95.	3.3	15
49	Prevention and management of multimorbidity to ensure healthcare sustainability. Annals of the Academy of Medicine, Singapore, 2021, 50, 807-808.	0.2	0
50	Zebrafish Model to Study Angiotensin II-Mediated Pathophysiology. Biology, 2021, 10, 1177.	1.3	1
51	MetodologÃa para analizar la carga financiera del cuidado familiar de una persona con enfermedad crónica. Revista Ciencias BiomÉdicas (cartagena), 2020, 6, 96-106.	0.0	4
52	Modeling Chronic Kidney Disease in TypeÂ2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. Diabetes Therapy, 2022, 13, 651-677.	1.2	0
53	Early Identification of CKD—A Scoping Review of the Global Populations. Kidney International Reports, 2022, 7, 1341-1353.	0.4	9
54	Socioeconomic Inequity in the Screening and Treatment of Hypertension in Kenya: Evidence From a National Survey., 2022, 2, .		6
55	The European Kidney Health Alliance (EKHA) and the Decade of the KidneyTM. Nephrology Dialysis Transplantation, 2023, 38, 1113-1122.	0.4	7
59	Reninâ $\in$ angiotensinâ $\in$ aldosterone pathway modulators in chronic kidney disease: A comparative review. Frontiers in Pharmacology, 0, 14, .	1.6	4
60	Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry. European Journal of Preventive Cardiology, 2023, 30, 960-968.	0.8	3

0

# ARTICLE IF CITATIONS

The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight). Pharmacoeconomics, 2023, 41, 573-587.